InvestorNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Advances Nanoparticle Drug Delivery, Prepares First-in-Human Study of IV Everolimus
January 9, 2026
Oncotelic Therapeutics (OTCQB: OTLC) is positioned at the heart of the evolving landscape of pharmaceutical innovation, applying ultra-small carrier technologies to elevate existing cancer therapies. “The company is pioneering how nanotechnology can enhance bioavailability, precision targeting and therapeutic performance of anticancer compounds,” reads a recent article. “The advantages of nanoparticle delivery in pharma are significant… […]
Oncotelic Therapeutics Inc. (OTLC) Unveils Breakthrough Nanomedicine Platform, Expands Everolimus (Afinitor(R)) Pipeline
December 23, 2025
Oncotelic Therapeutics (OTCQB: OTLC) is rapidly emerging as a key player in next-generation drug delivery, with a scalable nanotechnology platform that can transform the paradigms of immunology and oncology treatments. Leveraging Sapu Nano, the company’s clinical-stage nanomedicine, it unveiled new data at the 2025 San Antonio Breast Cancer Symposium (“SABCS”), highlighting that its Deciparticle(TM) platform […]
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Opens Research Access to PDAOAI Evidence Interrogation Platform
December 22, 2025
Oncotelic Therapeutics (OTCQB: OTLC) announced it has opened research access to PDAOAI, its proprietary evidence interrogation platform designed to extract biologically meaningful signals from large and complex biomedical datasets without training bespoke large language models on proprietary data. The company is also providing researchers access to a comprehensive TGF beta literature corpus comprising more than 125,000 PubMed abstracts through a dedicated Discord research channel, with […]
Oncotelic Therapeutics Inc. (OTLC) Leverages Nanoparticles to Re-Imagine Drug Delivery in Oncology
December 17, 2025
In the evolving landscape of pharmaceutical innovation, nanoparticles are rapidly transforming how we think about drug delivery, and Oncotelic Therapeutics (OTCQB: OTLC) is placing itself at the heart of that transformation by applying ultra-small carrier technologies to elevate existing cancer therapies. The company is pioneering how nanotechnology can enhance bioavailability, precision targeting and therapeutic performance […]
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Collaborates on Peer-Reviewed Biomarker Study in International Journal of Molecular Sciences
December 15, 2025
Oncotelic Therapeutics (OTCQB: OTLC), in collaboration with the Brush and Key Foundation, announced the publication of a peer-reviewed research article in the International Journal of Molecular Sciences titled “Comparative Tumor Microenvironment Analysis for HCC and PDAC Using KMplotter,” which analyzes the prognostic significance of biomarkers DNMT3A and GMPS across hepatocellular carcinoma and pancreatic ductal adenocarcinoma. […]
Antisense’s Moment: How Rational Design Is Rewriting Drug Development Economics
December 15, 2025
The pharmaceutical industry has long faced sobering odds: about 90% of drug candidates fail before reaching market. For small molecules, approval rates hover at very low odds, often requiring up to two decades of development. In oncology, success rates fall to just 3%. These economics have created a bottleneck that leaves patients waiting years for […]
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) identifies Biomarker Signature Predicting Sensitivity to IV Sapu003
December 4, 2025
Oncotelic Therapeutics (OTCQB: OTLC), reports that its 45% owned joint venture, Sapu Nano, has identified a High-RICTOR/Low-RPTOR molecular signature that predicts tumor sensitivity to Sapu003, the company’s intravenous Deciparticle(TM) formulation of everolimus. The biomarker framework, to be presented at the 2025 San Antonio Breast Cancer Symposium, is based on analysis of more than 9,000 tumor […]
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) 45% JV Reports IV Sapu003 Cuts GI Exposure to Everolimus by Up to 67-Fold
December 3, 2025
Oncotelic Therapeutics (OTCQB: OTLC), 45% owner of the Sapu Nano joint venture, announced new pharmacokinetic and tissue-distribution data showing that Sapu003, its intravenous Deciparticle (TM) formulation of everolimus, dramatically reduces gastrointestinal drug accumulation compared with oral everolimus. Oral dosing drives extreme gut exposure—up to 2,448× plasma levels in the stomach—while IV Sapu003 limits GI tissue […]
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) JV Sapu Nano Presents Data Showing Deciparticle Platform Supports Broad Hydrophobic Drug Formulation
December 2, 2025
Oncotelic Therapeutics (OTCQB: OTLC) said its 45%-owned joint venture, Sapu Nano, reported new data at the 2025 San Antonio Breast Cancer Symposium showing that its Deciparticle(TM) nanomedicine platform can consistently formulate structurally diverse hydrophobic therapeutics—including macrolide mTOR inhibitors, cyclic and linear peptides, ascomycin macrolactams and polyketides—into sub-20 nm nanoparticles suitable for IV delivery. The Company […]
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Rising Biotech Valuations
November 25, 2025
Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a BioMedWire editorial highlighting how fair-value adjustments under U.S. GAAP are emerging as key indicators of scientific and commercial progress across the biotech sector. The article spotlights Oncotelic’s upcoming fair-value update on its 45% ownership in JV partner GMP Bio, following an independent assessment showing a significant […]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Emerging as Leader with New Independent JV Valuation
November 21, 2025
NEW YORK, Nov. 21, 2025 (GLOBE NEWSWIRE) — via BioMedWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by BioMedWire (BMW), one of 75+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the […]
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in BioMedWire Editorial on Biotech Valuation Trends
November 21, 2025
Oncotelic Therapeutics (OTCQB: OTLC) was highlighted in a BioMedWire editorial examining how fair-value remeasurements under GAAP are becoming key indicators of real scientific and commercial progress in late-stage biotech pipelines. The piece notes that Oncotelic is preparing for a significant fair-value remeasurement of its 45% stake in JV entity GMP Bio following a new independent […]
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Reports Preliminary $1.7B Pipeline Valuation From Joint Venture Partner
November 20, 2025
Oncotelic Therapeutics (OTCQB: OTLC) today announced that joint venture partner GMP Bio has received an independent Frost & Sullivan (Hong Kong) valuation estimating the potential value of its therapeutic pipeline at approximately $1.7 billion, implying about $765 million for Oncotelic’s 45% stake. The non-binding, forward-looking analysis does not represent fair value under U.S. GAAP, and […]
Oncotelic Achieves Breakthrough $1.7 Billion Pipeline Valuation Through GMP Bio Joint Venture
November 20, 2025
SAN DIEGO, Nov. 20, 2025 (GLOBE NEWSWIRE) — via IBN — Oncotelic Therapeutics, Inc. (OTLC) today announces that its joint venture partner, GMP Bio, has completed an independent third-party valuation of its drug development pipeline. The preliminary valuation, conducted by Frost & Sullivan (Hong Kong), estimates the potential value of the joint venture’s therapeutic pipeline […]
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Sapu Bioscience Publish Landmark Review Defining Sub-15 nm Nanoparticles as New Frontier in Drug Delivery
November 11, 2025
Oncotelic Therapeutics (OTCQB: OTLC), and joint venture partner Sapu Bioscience today announced the publication of their review article, “Sub-15 nm Nanoparticles for Drug Delivery: Emerging Frontiers and Therapeutic Potential,” in the International Journal of Molecular Sciences (IJMS 2025, 26, 10842; https://doi.org/10.3390/ijms262210842). Authored by Dr. Tapas De, Vuong Trieu, Scott Myers, Sanjive Qazi, Saran Saund, and […]
InvestorNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Venture Begins Clinical Trials of Innovative Cancer Therapy
November 7, 2025
Oncotelic Therapeutics (OTCQB: OTLC) venture Sapu Nano recently secured approval from Australia’s Human Research Ethics Committee (“HREC”) to begin enrolling patients in clinical trials for Sapu003, an injectible form of Afinitor(R) (everolimus) for breast cancer treatment. Using Sapu Nano’s proprietary Deciparticle(TM) technology, Sapu003 delivers Everolimus directly into the bloodstream. “The approval of Sapu003 to enter […]
Sapu Nano Reveals the Initial In-Human Clinical Trial of Sapu-003, Intravenous Everolimus (Afinitor(R)) at Australian Translational Breast Cancer Symposium
November 3, 2025
Sapu Nano, which is in the Sapu family of companies, which was through GMP Biotechnology Limited, a joint venture between Oncotelic Therapeutics, Inc. (OTCQB: OTLC) and Dragon Overseas Capital Limited, recently revealed the company’s first in-human clinical trial of Sapu-003. The announcement occurred at the Australian Translational Breast Cancer Research Symposium (“ATBCR”). Sapu-003 is the […]
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) to Present Sapu003 Data at 2025 San Antonio Breast Cancer Symposium
October 31, 2025
Oncotelic Therapeutics (OTCQB: OTLC) a biopharmaceutical company advancing transformative cancer therapies through its PDAOAI platform and expertise in nanomedicines, announced that Sapu Nano’s investigational intravenous Deciparticle(TM) everolimus (Sapu003) has been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, Dec. 9–12, 2025, in San Antonio, Texas. Developed by Sapu Nano, a joint venture […]
NetworkNewsAudio Announces Audio Press Release (APR) on Transforming Once-Marginal Drugs into Category-Changing Assets
October 31, 2025
AUSTIN, Texas, Oct. 31, 2025 (GLOBE NEWSWIRE) — via IBN – NetworkNewsAudio announces the Audio Press Release (APR) title “Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology,” featuring Oncotelic Therapeutics Inc. (OTCQB: OTLC). To hear the NetworkNewsAudio version, visit https://nnw.fm/kSRbS To read the original editorial, visit https://nnw.fm/rbsvJ Within oncology, nanocarrier delivery has accelerated following regulatory validations such as FDA approvals of nanoparticle-formulated chemotherapies […]
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Nanomedicine Advances
October 30, 2025
Oncotelic Therapeutics (OTCQB: OTLC) announced its inclusion in a NetworkNewsWire (“NNW”) editorial titled “Nanomedicine Innovations Transforming Oncology Drug Delivery and Bioavailability.” The feature highlights how breakthroughs in nanocarrier-based delivery are reshaping cancer therapy by enhancing efficacy and reducing toxicity. Oncotelic’s proprietary Deciparticle(TM) platform is spotlighted for its potential to improve the bioavailability and therapeutic index […]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) at Forefront of Effort to Optimize Next-Generation Cancer Therapies
October 30, 2025
NEW YORK, Oct. 30, 2025 (GLOBE NEWSWIRE) — via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the […]
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Nanomedicine Innovations in Oncology
October 28, 2025
Oncotelic Therapeutics (OTCQB: OTLC) today announced its inclusion in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within the Dynamic Brand Portfolio @ IBN (InvestorBrandNetwork), a communications platform specializing in financial news and content distribution. The article, titled “Nanomedicine Breakthrough Technology Redefining Drug Delivery, Bioavailability in Oncology,” highlights how nanocarrier-based delivery systems are […]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Working to Transform Underperforming Compounds into Next-Gen Cancer Therapies
October 28, 2025
NEW YORK, Oct. 28, 2025 (GLOBE NEWSWIRE) — via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the […]
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Three Accepted Abstracts on Deciparticle (TM) Everolimus (Sapu003) at 2025 San Antonio Breast Cancer Symposium
October 23, 2025
Oncotelic Therapeutics (OTCQB: OTLC), a biopharmaceutical company developing transformative cancer therapies through its PDAOAI platform and expertise in nanomedicines, announced that three abstracts featuring its investigational intravenous Deciparticle (TM) everolimus (Sapu003) have been accepted for presentation at the 2025 San Antonio Breast Cancer Symposium, to be held Dec. 9–12 in San Antonio, Texas. Developed by […]
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Return of Dr. Vuong Trieu, CEO of Oncotelic Therapeutics Inc.
October 22, 2025
AUSTIN, Texas, Oct. 22, 2025 (GLOBE NEWSWIRE) — via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews […]
Nanomedicine’s Next Leap: Why Particle Size Matters in Cancer Drug Delivery
October 21, 2025
Oncotelic Therapeutics Inc. (OTCQB: OTLC) is advancing precision nanomedicine with its proprietary Deciparticle(TM) platform, beginning human trials for Sapu003, a 20nm nanoparticle formulation of Everolimus (Afinitor(R)). This scientific briefing explores why particle size is critical to drug efficacy, how Oncotelic’s technology enhances tumor targeting, and how its rapid IND platform accelerates clinical development across multiple […]
InvestorNewsBreaks – Oncotelic Therapeutics Inc. (OTLC) Positioned to Fill Critical Gaps in Cancer Care with RNA and Small-Molecule Therapies
October 17, 2025
Oncotelic Therapeutics (OTCQB: OTLC) was featured in a recent article that discussed its efforts to pioneer RNA candidates and strategic programs aimed at some of the most lethal and overlooked cancers. “Immunotherapy and RNA-based approaches have begun to reshape the understanding of cancer treatment. The FDA approved 17 new immunotherapies in 2024 alone, spanning multiple […]
Oncotelic Therapeutics Inc.’s (OTLC) Sapu003: Injectable Everolimus (Afinitor(R)) to Begin Clinical Trials, Aiming to Boost Drug Bioavailability
October 8, 2025
Oncotelic Therapeutics (OTCQB: OTLC) is a clinical-stage biopharmaceutical company advancing a diversified pipeline spanning oncology, immunotherapy, neurodegeneration, and rare diseases. In a recent interview on the BioMedWire podcast, Chairman and CEO Dr. Vuong Trieu emphasized the company’s unique model: focusing on de-risked, late-stage assets and accelerating their development through regulatory pathways designed for speed and […]
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Announces Phase 1 Trial of Sapu-003, a Novel Intravenous Deciparticle(TM) Everolimus, Now Open for Enrollment in Australia
October 8, 2025
Oncotelic Therapeutics (OTCQB: OTLC), through its joint venture GMP Biotechnology Ltd. with Dragon Overseas Capital Ltd., announced that Sapu Nano presented its poster, “Sapu-003: Novel Intravenous Deciparticle(TM) Everolimus Entering Phase 1 Study in Australia,” at the 8th Australian Translational Breast Cancer Research Symposium (ATBCR 2025). The study marks the first clinical trial of an intravenous […]
Sapu Nano Unveils First-in-Human Clinical Trial of Sapu-003 at 8th Australian Translational Breast Cancer Research Symposium
October 8, 2025
SYDNEY, Australia, Oct. 08, 2025 (GLOBE NEWSWIRE) — via IBN – Sapu Nano today announced the presentation of its poster, “Sapu-003: Novel Intravenous Deciparticle™ Everolimus Entering Phase 1 Study in Australia,” at the 8th Australian Translational Breast Cancer Research Symposium (ATBCR 2025). Sapu Nano is part of the Sapu family of companies, formed through GMP Biotechnology Limited, […]
Oncotelic Therapeutics Inc. (OTLC) Venture Sapu Nano Receives Approval to Begin Human Clinical Trials of Sapu003, an Injectible Form of Afinitor(R) (Everolimus) for Breast Cancer Treatment
October 1, 2025
Sapu Nano, part of a group of companies formed through GMP Biotechnology Limited, which is a joint venture between Oncotelic Therapeutics (OTCQB: OTLC) and Dragon Overseas Capital Limited, recently received approval from the HREC in Australia to begin enrolling people in clinical trails of Sapu003 for the treatment of breast cancer. Sapu003 is an injectible […]
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Joint Venture Sapu Nano Receives Approval to Begin Phase 1 Trial of Injectable Everolimus for Breast Cancer
September 24, 2025
Oncotelic Therapeutics (OTCQB: OTLC) announced that its joint venture through GMP Biotechnology Limited, Sapu Nano, has received approval from Australia’s Human Research Ethics Committee to begin enrolling patients in a Phase 1 human clinical trial of Sapu003, an injectable form of Everolimus for breast cancer. Everolimus, marketed as Afinitor(R), is FDA-approved in oral form but […]
Sapu Nano’s Sapu003 Advances to Human Clinical Testing – Transforming Everolimus Delivery with Full Bioavailability for Breast Cancer Patients
September 24, 2025
SAN DIEGO, Sept. 24, 2025 (GLOBE NEWSWIRE) — via IBN — Sapu Nano, developer of Deciparticle™, today announced that it has received approval from Australia’s Human Research Ethics Committee (HREC) to begin enrolling patients in a Phase 1 human clinical trial of Sapu003—an injectable form of Everolimus—for the treatment of breast cancer. Sapu Nano is […]
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) CEO Featured on IBN’s BioMedWire Podcast
September 22, 2025
Oncotelic Therapeutics (OTCQB: OTLC), a clinical-stage biopharmaceutical company developing transformative oncology and immunotherapy treatments, is featured in the latest episode of IBN’s BioMedWire Podcast. Chairman and CEO Dr. Vuong Trieu discussed the company’s mission to treat cancer and rare diseases, emphasizing Oncotelic’s expertise in tumor microenvironments, regulatory pathways, and intellectual property strategies. He noted that […]
IBN Announces Latest Episode of The BioMedWire Podcast Featuring Dr. Vuong Trieu, CEO of Oncotelic Therapeutics Inc.
September 22, 2025
AUSTIN, Texas, Sept. 22, 2025 (GLOBE NEWSWIRE) — via IBN – IBN, a multifaceted communications organization engaged in connecting public companies to the investment community, is pleased to announce the release of the latest episode of The BioMedWire Podcast as part of its sustained effort to provide specialized content distribution via widespread syndication channels. The BioMedWire Podcast delivers dynamic interviews […]
Oncotelic Therapeutics Inc. (OTLC): Leadership and Innovation Drive Late-Stage Biotech Momentum
September 19, 2025
The biotechnology sector is defined by its ability to pair scientific innovation with leadership that can translate discoveries into approved therapies. This is particularly critical in oncology, where late-stage candidates must navigate complex regulatory pathways and demonstrate real clinical impact in indications with limited treatment options. Companies that combine robust intellectual property with seasoned leadership […]
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsAudio Release on Innovative Therapeutics Pipeline
September 19, 2025
Oncotelic Therapeutics (OTCQB: OTLC) is featured in a new NetworkNewsAudio Audio Press Release (APR) titled “Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth.” The release highlights the leadership of chair and CEO Dr. Vuong Trieu, who has filed more than 500 patent applications and holds 75 issued patents spanning oncology, immunotherapy and nanomedicine. Dr. […]
NetworkNewsAudio Announces Audio Press Release (APR) on Innovation in Cancer, Rare Disease Treatment Space
September 19, 2025
AUSTIN, Texas, Sept. 19, 2025 (GLOBE NEWSWIRE) — via IBN – NetworkNewsAudio announces the Audio Press Release (APR) titled “Innovative Therapeutics Pipeline Positions Industry for Strong Market Growth,” featuring Oncotelic Therapeutics Inc. (OTCQB: OTLC). To hear the NetworkNewsAudio version, visit https://nnw.fm/9ywu8 To read the original editorial, visit https://nnw.fm/DVT8m At the helm of Oncotelic is Dr. Vuong Trieu, a biotech leader with a […]
InvestorNewsBreaks – Oncotelic Therapeutics, Inc. (OTCQB: OTLC) Featured in NetworkNewsWire Editorial on Advancing Cancer Research
September 18, 2025
Oncotelic Therapeutics (OTCQB: OTLC) today announced its placement in an editorial published by NetworkNewsWire (“NNW”) titled “Advancing Cancer Research Brings New Hope for Patients Worldwide.” The article highlights the urgent need for innovation in treating deadly cancers such as glioblastoma and pancreatic cancer, as well as rare pediatric disorders. Under the leadership of chair and […]
Oncotelic Therapeutics Inc. (OTCQB: OTLC) Creating Pioneering Pipeline Designed to Transform Cancer, Rare Diseases Treatments
September 18, 2025
NEW YORK, Sept. 18, 2025 (GLOBE NEWSWIRE) — via InvestorWire — Oncotelic Therapeutics Inc. (OTCQB: OTLC) today announces its placement in an editorial published by NetworkNewsWire (“NNW”), one of 70+ brands within the Dynamic Brand Portfolio@IBN (InvestorBrandNetwork), a specialized communications platform with a focus on financial news and content distribution for private and public companies and the investment community. To view the […]